Plain-English translation of NCT07183878 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study compares two ways to prepare patients with aggressive blood cancers (acute myeloid leukemia or myelodysplastic syndrome) for a stem cell transplant from a donor. One group receives standard chemotherapy preparation, while the other group receives the same chemotherapy plus , a newer medication that targets cancer cells. The goal is to see if adding this medication reduces the chance that the cancer comes back after transplant.
Even with strong chemotherapy before transplant, cancer often returns in patients with high-risk blood cancers, and doctors believe some leukemia cells survive standard treatment. This medication has shown promise in killing these hard-to-treat cancer cells, and researchers want to know if it can improve long-term survival when combined with transplant.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either standard transplant preparation or standard preparation plus the new medication. You will visit the hospital for intensive chemotherapy and conditioning treatment for about two weeks before receiving donated stem cells. After transplant, you will have weekly check-ups for one month, then monthly visits for six months, and every three months for up to three years, with blood tests and scans to monitor your recovery and watch for cancer returning.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China